A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
← catalyst calendarNCT07231991 · readout in 106 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Arvinas Estrogen Receptor, Inc..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
24estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-18 | actual | When the study began enrolling |
| Primary completion | 2026-12-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Intervention
- Drug: vepdegestrant — also filed as ARV-471, PF-07850327
Primary outcomes
what the primary-completion date above is the date OFMaximum observed concentration (Cmax) for vepdegestrant
measured Pre-dose, and 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, and 216 hours post dose
Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for vepdegestrant
measured Pre-dose, and 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, and 216 hours post dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed